Recent Quotes (30 days)

You have no recent quotes
chg | %

Arch Biopartners Inc  

(Public, CNSX:ACH)   Watch this stock  
Find more results for ACH
Feb 20 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 0.42
Open     -
Vol. 0.00
Mkt cap 21.41M
P/E     -
Div/yield     -
EPS -0.01
Shares 50.98M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -954.44% -779.41%
Operating margin -973.09% -772.74%
EBITD margin - -699.96%
Return on average assets -407.50% -180.07%
Return on average equity - -
CDP Score - -


174 Spadina Avenue Suite 502A
+1-647-4287031 (Phone)
+1-905-7704454 (Fax)

Website links


Arch Biopartners Inc. (Arch) is a Canada-based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company has three technology platforms in its portfolio under development (each within its own subsidiary): MetaMx, is a peptides that target brain tumor initiating cells and invasive glioma cells; Borg Peptides, which binds peptides to solid surfaces, and treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. The Metablok, a new drug candidate of the Company in its development pipeline as a potential treatment for sepsis and cancer metastasis.The Company�s three wholly owned subsidiaries include Arch Cancer Therapeutics Ltd.; Arch Biotech Inc., and Arch Biophysics.

Officers and directors

Richard Muruve President, Chief Executive Officer, Director
Daniel Muruve Chief Science Officer
Andrew Bishop Director
Richard Rossman M.D. Director
Claude Allary Independent Director
Conor M. Gunne Independent Director
Adrian J Haigh Independent Director